Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tancredi Didier Bazan Russo
Observed names:
T. Bazan Russo,
T.D. Bazan Russo
Institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
University of Palermo
Observed institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
University of Palermo
ORCID:
0009-0007-5595-3924
Observed ORCID:
0009-0007-5595-3924
OpenAlex ID:
A5007772500
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
2022
·
Daniele Fanale
, Alessandra Dimino
, et al.
·
Cancers
·
60
PDF
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
2024
·
Tancredi Didier Bazan Russo
, Clarissa Mujacic
, et al.
·
Cancer Gene Therapy
·
49
PDF
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors
2024
·
Lorena Incorvaia
, Tancredi Didier Bazan Russo
, et al.
·
npj Precision Oncology
·
48
PDF
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
2022
·
Daniele Fanale
, Lidia Rita Corsini
, et al.
·
Critical Reviews in Oncology/Hematology
·
41
MUTYH-associated tumor syndrome: The other face of MAP
2022
·
Luigi Magrin
, Daniele Fanale
, et al.
·
Oncogene
·
40
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
2023
·
Lorena Incorvaia
, Alessandro Perez
, et al.
·
Cancer Treatment Reviews
·
37
PDF
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible
2022
·
Valerio Gristina
, Maria La Mantia
, et al.
·
Critical Reviews in Oncology/Hematology
·
26
PDF
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
2022
·
Antonio Galvano
, Luisa Castellana
, et al.
·
Therapeutic Advances in Medical Oncology
·
26
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer
2025
·
Tancredi Didier Bazan Russo
, Francesco Pepe
, et al.
·
Future Oncology
·
25
PDF
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
2022
·
Valerio Gristina
, Nadia Barraco
, et al.
·
Cancers
·
25
PDF
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning
2022
·
Daniele Fanale
, Alessia Pivetti
, et al.
·
Critical Reviews in Oncology/Hematology
·
23
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength
2022
·
Daniele Fanale
, Lidia Rita Corsini
, et al.
·
Frontiers in Oncology
·
21
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
2023
·
Lorena Incorvaia
, Gaetana Rinaldi
, et al.
·
Therapeutic Advances in Medical Oncology
·
19
POLE-mutated endometrial cancer: new perspectives on the horizon?
2025
·
Daniele Fanale
, Lidia Rita Corsini
, et al.
·
Frontiers in Oncology
·
16
PDF
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer
2024
·
Andrea Gottardo
, Tancredi Didier Bazan Russo
, et al.
·
Cytopathology
·
15
PDF
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”
2024
·
Andrea Gottardo
, Valerio Gristina
, et al.
·
The Journal of Liquid Biopsy
·
15
PDF
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?
2023
·
Daniele Fanale
, Lidia Rita Corsini
, et al.
·
Critical Reviews in Oncology/Hematology
·
15
PDF
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study
2025
·
L. Incorvaia
, C. Marchetti
, et al.
·
ESMO Open
·
13
PDF
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
2022
·
Daniele Fanale
, Lidia Rita Corsini
, et al.
·
Frontiers in Oncology
·
13
PDF
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
2023
·
Daniele Fanale
, Chiara Brando
, et al.
·
BMC Cancer
·
12
PDF
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
2023
·
Lorena Incorvaia
, Alessandra Dimino
, et al.
·
Frontiers in Oncology
·
12
PDF
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints
2023
·
Daniele Fanale
, Lidia Rita Corsini
, et al.
·
Critical Reviews in Oncology/Hematology
·
11
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
2022
·
Alessandra Dimino
, Chiara Brando
, et al.
·
Cancers
·
11
PDF
Genomics and the early diagnosis of lung cancer
2025
·
Francesco Pepe
, Tancredi Didier Bazan Russo
, et al.
·
Personalized Medicine
·
10
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients
2024
·
Valerio Gristina
, Tancredi Didier Bazan Russo
, et al.
·
Scientific Reports
·
10
Show more works
View as search
Works count:
80
Citation count:
685
H-index:
15
I10-index:
25
Year
Topic
Type